Michael J. Cieslewicz
Corporate Officer/Principal at Vigeo Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jing Watnick | M | - |
Vigeo Therapeutics, Inc.
 Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | 13 years |
| Jim Mahoney | M | - |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | 8 years |
| Jim Mahoney | - | - |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | 9 years |
| Daniel Geffken | M | 67 |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | 7 years |
| Stephanie O'Brien | F | 65 |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | - |
| Westley Nolin | M | - |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael J. Cieslewicz
- Personal Network
